According to MannKind Corp's latest financial reports the company has a price-to-book ratio of -4.49.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | -3.99 | -28% |
2022-12-31 | -5.54 | 5.56% |
2021-12-31 | -5.24 | 28.28% |
2020-12-31 | -4.09 | 185.12% |
2019-12-31 | -1.43 | 26.64% |
2018-12-31 | -1.13 | -11.83% |
2017-12-31 | -1.28 | -22.59% |
2016-12-31 | -1.66 | -6.5% |
2015-12-31 | -1.77 | -93.82% |
2014-12-31 | -28.7 | -54.1% |
2013-12-31 | -62.5 | 947.62% |
2012-12-31 | -5.97 | 470.27% |
2011-12-31 | -1.05 | -81.14% |
2010-12-31 | -5.55 | -66.79% |
2009-12-31 | -16.7 | -514.44% |
2008-12-31 | 4.03 | 82.01% |
2007-12-31 | 2.22 | -29.74% |
2006-12-31 | 3.15 | 79.01% |
2005-12-31 | 1.76 | -48.06% |
2004-12-31 | 3.39 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Pfizer PFE | 1.61 | -135.88% | ๐บ๐ธ USA |
Novo Nordisk NVO | 34.7 | -873.26% | ๐ฉ๐ฐ Denmark |
Eli Lilly LLY | 65.3 | -1,554.75% | ๐บ๐ธ USA |
Merck MRK | 8.43 | -287.82% | ๐บ๐ธ USA |
Halozyme Therapeutics HALO | 57.3 | -1,377.29% | ๐บ๐ธ USA |
Nektar Therapeutics
NKTR | 1.85 | -141.23% | ๐บ๐ธ USA |